Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis

Sickle Cell Disease Clinical Trial

Official title:

A Phase 2 Multi-center, Randomized, Double-blind, Comparator-Controlled Dose Finding Study to Evaluate MP4CO for the Acute Treatment of Vaso-occlusive Crises in Subjects With Sickle Cell Disease

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01925001
• Other study ID #: SCD-206
• Status: Withdrawn
• Phase: Phase 2
• First received: August 14, 2013
• Last updated: October 25, 2013
• Start date: October 2013
• Est. completion date: October 2015

Study information

• Verified date: October 2013
• Source: Sangart
• Contact: n/a
• Is FDA regulated: No
• Health authority: Bahrain: Ethics CommitteeBelgium: Federal Agency for Medicines and Health Products, FAMHPBrazil: National Health Surveillance AgencyFrance: Agence Nationale de Sécurité du Médicament et des produits de santéItaly: National Monitoring Centre for Clinical Trials - Ministry of HealthLebanon: Ministry of Public HealthNetherlands: The Central Committee on Research Involving Human Subjects (CCMO)Oman: Academic Accreditation AuthorityQatar: Hamad Medical CorporationSaudi Arabia: Ministry of HealthTurkey: Ministry of HealthUnited Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

Sickle Cell disease is caused by an inherited hemoglobin disorder. Healthy red blood cells are discoid and can deform and move through small blood vessels to carry oxygen to all parts of the body. In Sickle Cell disease, as red blood cells circulate and oxygen is released, the deoxygenated abnormal Hemoglobin S can begin to polymerize and cause red cells to become sticky and elongated. These "sickled" red cells are less flexible and will obstruct small blood vessels and prevent normal red cells from circulating freely, which limits oxygen delivery to tissues and organs. This is known as a "sickling crisis" or "vaso-occlusive crisis" and is the leading cause of hospitalization in patients with Sickle Cell disease.

Patients suffering from a sickle crisis experience severe pain and are at risk of stroke, heart attack or even death. Current therapy is limited to hydration and symptomatic pain relief. The administration of MP4CO as an adjunct treatment to standard therapy may alleviate pain associated with a sickling crisis and potentially reduce the severity and duration of a crisis. This may shorten the time in hospital and potentially improve the quality of life for patients with sickle cell anemia.

Description:

Sickle cell disease (SCD) is an autosomal recessive disorder of the β globin gene of the hemoglobin molecule. To date, no specific agent has been approved to treat a sickle cell crisis, to reduce the severity of a sickling crisis, or to shorten the duration of admission. Current therapy for a crisis is limited to hydration and symptomatic pain relief with opiates when pain is severe enough to cause admission to hospital. Administration of oxygen by inhalation alone has not proven effective. The carbon monoxide (CO) molecule binds to Hb S and, while attached, prevents and reverses polymerization of Hb S chains and the distortion of the red cell. CO at very low doses also acts as a cell-signaling molecule, and may reduce inflammation, decrease oxygen requirements, and prevent programmed cell death (apoptosis).

MP4CO is designed as an ischemic rescue therapy to deliver non-toxic levels of CO, to provide an immediate metabolic signal to cells to help reverse red cell sickling, and to reduce inflammation.

Previously published studies provide a foundation to postulate that MP4CO might have the appropriate properties for treatment or reversal of an acute sickling crisis. The initial release of CO from MP4CO is predicted to have a beneficial effect including immediate stabilization of Hb S to prevent further red cell polymerization and reverse existing sickling, dilation of capillaries to enhance tissue perfusion, and anti-inflammatory cell-signalling properties. The subsequent circulation of the MP4 molecule as an oxygen therapeutic (after converting to MP4OX following oxygenation in the lungs) will help to 1) preferentially oxygenate ischemic tissue, 2) reverse partially sickled red cells, and 3) improve perfusion and oxygenation of local tissues to potentially ameliorate the painful crisis caused by sickling of red cells. In addition, MP4CO has enhanced chemical stability, which enables storage at room temperature.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Signed Informed Consent (and assent as required for minors)

• Diagnosis of SCD (known HbSS or HbSß0)

• Sixteen years of age or older

• Prior history of at least one VOC requiring hospitalization within the last 24 months

Exclusion Criteria:

• = 5 VOCs within the preceding 6 months requiring Emergency Room (ER) visits or hospital admissions

• History of overt stroke or cerebral vascular accident within the previous 12 months

• Remained in the hospital for =2 weeks (14 days) for VOC management within the previous 6 months

• Known pulmonary hypertension based on an estimated tricuspid regurgitant jet velocity (TRJV) >2.90 m/s or definitive diagnosis by prior right heart catheterization

• Baseline SaO2 level by pulse oximetry <92% on room air

• Systemic hypertension (baseline systolic pressure = 160 mmHg or diastolic pressure = 90 mmHg)

• History of myocardial infarction, myocardial ischemia, or angina

• On a chronic red blood cell transfusion therapy program (simple or exchange)

• Renal dysfunction presenting with a GFR<60 mL/min/1.73m

• Any diagnosis of a concurrent chronic debilitating disease that may affect the completion of the study or results of the study as determined by the investigator

• Currently enrolled in any other investigational treatment study

• Significant substance abuse.

• Known to have HIV, active hepatitis B, or C infection, or active tuberculosis

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Anemia
• Anemia, Sickle Cell
• Hemoglobin SC Disease
• Sickle Cell Anemia
• Sickle Cell Disease
• Sickle Cell Disorders
• Sickle Cell Hemoglobin C Disease

Intervention

Drug:
• MP4CO
43 mg/mL pegylated carboxyhemoglobin [= 90% CO hemoglobin saturation] in physiological acetate electrolyte solution
• Sodium chloride solution
Normal saline solution (0.9% Sodium Chloride Injection USP)

Locations

Country	Name	City	State
Bahrain	Salmaniya Medical Complex	Manama
Belgium	University Hospital Brugmann	Brussels
Brazil	Rio de Janerio Instituto Estadual de Hematologie	Rio de Janerio
France	Hôpital Henri Mondor	Créteil
France	Georges Pompidou European University Hospital	Paris
Lebanon	American Univ. of Beirut Medical Center	Beirut
Lebanon	Univ. Medical Center Rizk Hospital	Beirut
Netherlands	Academic Medical Center	Amsterdam
Qatar	Cornell Medical City	Doha
Turkey	Cukurova University Medical Facilty	Adana
Turkey	Mersin University Medical Faculty	Mersin
United Kingdom	Guys Hospital	London
United Kingdom	King's College Hospital	London
United Kingdom	Queen Mary Hospital	London

Sponsors (1)

Lead Sponsor	Collaborator
Sangart

Countries where clinical trial is conducted

Bahrain,  Belgium,  Brazil,  France,  Lebanon,  Netherlands,  Qatar,  Turkey,  United Kingdom, 

References & Publications (14)

Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood. 2012 Nov 1;120(18):3647-56. doi: 10.1182/blood-2012-04-383430. Epub 2012 Aug 24. Review. — View Citation

Belcher JD, Mahaseth H, Welch TE, Otterbein LE, Hebbel RP, Vercellotti GM. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest. 2006 Mar;116(3):808-16. Epub 2006 Feb 16. — View Citation

Belcher JD, Young M, Chen C, Nguyen J, Burhop K, Tran P, Vercellotti GM. MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation, and vaso-occlusion in transgenic sickle mice. Blood. 2013 Oct 10;122(15):2757-64. doi: 10.1182/blood-2013-02-486282. Epub 2013 Aug 1. — View Citation

Bilban M, Haschemi A, Wegiel B, Chin BY, Wagner O, Otterbein LE. Heme oxygenase and carbon monoxide initiate homeostatic signaling. J Mol Med (Berl). 2008 Mar;86(3):267-79. Epub 2007 Nov 22. Review. — View Citation

Cole RH, Vandegriff KD. MP4, a vasodilatory PEGylated hemoglobin. Adv Exp Med Biol. 2011;701:85-90. doi: 10.1007/978-1-4419-7756-4_12. — View Citation

Piantadosi CA, Withers CM, Bartz RR, MacGarvey NC, Fu P, Sweeney TE, Welty-Wolf KE, Suliman HB. Heme oxygenase-1 couples activation of mitochondrial biogenesis to anti-inflammatory cytokine expression. J Biol Chem. 2011 May 6;286(18):16374-85. doi: 10.1074/jbc.M110.207738. Epub 2011 Mar 18. — View Citation

Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore). 2005 Nov;84(6):363-76. — View Citation

Svergun DI, Ekström F, Vandegriff KD, Malavalli A, Baker DA, Nilsson C, Winslow RM. Solution structure of poly(ethylene) glycol-conjugated hemoglobin revealed by small-angle X-ray scattering: implications for a new oxygen therapeutic. Biophys J. 2008 Jan 1;94(1):173-81. Epub 2007 Sep 7. — View Citation

Tsai AG, Cabrales P, Manjula BN, Acharya SA, Winslow RM, Intaglietta M. Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers. Blood. 2006 Nov 15;108(10):3603-10. Epub 2006 Jul 20. — View Citation

Tsai AG, Vandegriff KD, Intaglietta M, Winslow RM. Targeted O2 delivery by low-P50 hemoglobin: a new basis for O2 therapeutics. Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1411-9. Epub 2003 Jun 12. — View Citation

Vandegriff KD, Bellelli A, Samaja M, Malavalli A, Brunori M, Winslow RM. Kinetics of NO and O2 binding to a maleimide poly(ethylene glycol)-conjugated human haemoglobin. Biochem J. 2004 Aug 15;382(Pt 1):183-9. — View Citation

Vandegriff KD, Malavalli A, Mkrtchyan GM, Spann SN, Baker DA, Winslow RM. Sites of modification of hemospan, a poly(ethylene glycol)-modified human hemoglobin for use as an oxygen therapeutic. Bioconjug Chem. 2008 Nov 19;19(11):2163-70. doi: 10.1021/bc8002666. — View Citation

Vandegriff KD, McCarthy M, Rohlfs RJ, Winslow RM. Colloid osmotic properties of modified hemoglobins: chemically cross-linked versus polyethylene glycol surface-conjugated. Biophys Chem. 1997 Nov;69(1):23-30. — View Citation

Vandegriff KD, Young MA, Lohman J, Bellelli A, Samaja M, Malavalli A, Winslow RM. CO-MP4, a polyethylene glycol-conjugated haemoglobin derivative and carbon monoxide carrier that reduces myocardial infarct size in rats. Br J Pharmacol. 2008 Aug;154(8):1649-61. doi: 10.1038/bjp.2008.219. Epub 2008 Jun 9. — View Citation

* Note: There are 14 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Adverse events	Adverse events (AEs) assessed daily through 7 days, and Serious Adverse Events (SAEs) throughout Day 28 follow-up visit	Up to 28 days	Yes
Other	Urine biomarkers	Urinalysis, and biomarkers to evaluate renal function	Up to 7 days	Yes
Other	Ambulation	Ability to ambulate assessed by Chair Rise and 50-foot walk tests	Daily up to 7 days	No
Other	Pain diary	Electronic diary recording of daily pain levels using a visual analogue scale (VAS)	Up to 1 year (on average)	No
Primary	Duration of hospitalization for treatment of painful vaso-occlusive crisis (VOC)	Time from randomization to resolution of the vaso-occlusive crisis, assessed by evaluation of cessation of opioid analgesia, recovery of ambulation, and/or ready for hospital discharge.	Up to 28 days	No
Secondary	Pain levels	Proportion of subjects with a pre-defined reduction in pain levels assessed using a visual analogue scale (VAS)	Up to 7 days	No
Secondary	Readmission to emergency room (ER)	Proportion of subjects with at least one return visit to ER after hospital discharge	Up to 28 days	No
Secondary	Re-admission to hospital for treatment of VOC	Proportion of subjects re-admitted to hospital for VOC treatment within 7 days after discharge	Up to 28 days	No
Secondary	Acute Chest Syndrome (ACS) complications	Proportion of subjects with ACS complications	Up to 28 days	Yes

External Links

•   Sangart, Inc. (Sponsor home page)